Herpes



Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax vaccine
Sponsor:   HaEmek Medical Center, Israel
Recruiting - verified February 2017


Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2017


Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes


Condition:   Herpes Labialis
Interventions:   Drug: Pritelivir 5% w/w ointment;   Drug: Pritelivir ointment matching placebo;   Drug: Zovirax® cream
Sponsors:   AiCuris Anti-infective Cures GmbH;   Novella Clinical
Recruiting - verified February 2017


Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine


Condition:   Herpes Genitalis
Interventions:   Biological: VCL-HB01;   Other: Phosphate-buffered saline
Sponsor:   Vical
Active, not recruiting - verified April 2017


Herpes Zoster Prevalence in Frailty Consultations


Condition:   Herpes Zoster
Intervention:   Other: Medical Questionary
Sponsor:   University Hospital, Toulouse
Completed - verified July 2016



Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017


Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis


Condition:   Herpes Labialis
Interventions:   Other: BOR15001L7;   Other: Placebo
Sponsor:   Laboratoire Boreaderme Inc.
Recruiting - verified March 2017


Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Boostrix
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults


Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: VCL-HB01;   Biological: VCL-HM01;   Biological: PBS
Sponsor:   Vical
Completed - verified July 2016


Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older


Condition:   Herpes Zoster
Intervention:   Biological: Herpes zoster vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


Herpes Zoster Vaccine for Bone Marrow Transplant Donors


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   University of Sydney
Recruiting - verified May 2017


Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects


Condition:   Herpes Zoster
Intervention:   Procedure: Blood sample
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor:   GlaxoSmithKline
Completed - verified May 2017


Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease


Condition:   Herpes Simplex
Interventions:   Biological: Herpes simplex candidate vaccine- adjuvanted GSK208141;   Biological: Placebo injection
Sponsor:   GlaxoSmithKline
Completed - verified September 2016


Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old


Condition:   Herpes Simplex
Interventions:   Biological: GSK208141;   Biological: HavrixTM (investigational formulation);   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine


Condition:   Herpes Simplex
Intervention:   Biological: GSK208141 vaccine
Sponsor:   GlaxoSmithKline
Completed - verified September 2016


Refine Your Search Advanced Search